Wyeth’s Successful R&D Renovation: Neuroscience Shows Early Returns
Executive Summary
Six months after unveiling its "Project Springboard" efficiency initiative, Wyeth is holding up its neurosciences portfolio as an example of the success of the work-in-progress transformation of the company's R&D business
You may also be interested in...
Pipeline Dreams: GSK’s Witty Outlines Plans To Lower Phase III Attrition
As Andrew Witty takes the helm at GlaxoSmithKline, he has set his sights on tackling one of the industry's biggest challenges: reducing attrition in the late-stage pipeline
Pipeline Dreams: GSK’s Witty Outlines Plans To Lower Phase III Attrition
As Andrew Witty takes the helm at GlaxoSmithKline, he has set his sights on tackling one of the industry's biggest challenges: reducing attrition in the late-stage pipeline
Poussot Tapped As Wyeth CEO – Inherits Full Pipeline, Takeover Concerns
With the appointment of 20-year veteran Bernard Poussot as CEO, Wyeth is following a traditional approach to chief exec succession -avoiding drama by selecting a well-groomed insider with the standard pedigree from the business and marketing sides of the operation